follow up of participants in a previous study of quadrivalent meningitis vaccine.

Phase 1

• Conditions: o specific medical condition(s) - responses to vaccination against meningococcal disease.; MedDRA version: 19.0 Level: PT Classification code 10027199 Term: Meningitis System Organ Class: 10021881 - Infections and infestations; Therapeutic area: Body processes [G] - Immune system processes [G12]

• Registration Number: EUCTR2016-002381-31-GB
• Lead Sponsor: Public Health England

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-07-21
• Study Completion: 2017-08-31
• Last Update Posted: 30 April 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 57

Inclusion Criteria

•Individual is willing and able to give written informed consent for participation.
•Individual was originally enrolled in the randomised parallel group study of quadrivalent meningococcal vaccination.

Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 93
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

•Known bleeding diathesis (or any condition that may be associated with a prolonged bleeding time).
•Any other significant condition or circumstance which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified